Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Sumitomo Dainippon Pharma Co Ltd    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO LTD

(4506)
My previous session
Most popular
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 462 B
EBIT 2019 -
Net income 2019 41 011 M
Finance 2019 131 B
Yield 2019 0,76%
Sales 2020 471 B
EBIT 2020 -
Net income 2020 44 474 M
Finance 2020 157 B
Yield 2020 0,75%
P/E ratio 2019 26,37
P/E ratio 2020 25,67
EV / Sales2019 2,10x
EV / Sales2020 2,00x
Capitalization 1 099 B
More Financials
Company
Dainippon Sumitomo Pharma Co. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (90.8%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems... 
More about the company
Surperformance© ratings of Sumitomo Dainippon Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on SUMITOMO DAINIPPON PHARMA
03/13SUMITOMO DAINIPPON PHARMA : Sumitomo Chemical Announces the New Corporate Busine..
AQ
03/04SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma announces Organizational R..
AQ
03/04SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma Expands Roles and Responsi..
AQ
02/11SUMITOMO DAINIPPON PHARMA : and Aikomi Conclude Joint Research Agreement on Medi..
AQ
01/31SUMITOMO DAINIPPON PHARMA CO LTD : 3rd quarter results
CO
01/30SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma Announces the Approval of ..
AQ
01/30SUMITOMO DAINIPPON PHARMA : SanBio and Sumitomo Dainippon Pharma Announce Toplin..
AQ
01/30SanBio's crash causes margin calls, drags down Japan's start-up market
RE
01/29UPDATE1 : Tokyo stocks fall in morning, hit by drugmakers' poor performance
AQ
01/29Nikkei falls as Dainippon Pharma offsets Apple optimism
RE
More news
Analyst Recommendations on SUMITOMO DAINIPPON PHARMA
More recommendations
Sector news : Pharmaceuticals - NEC
08:57aBAYER : CEO says his team retains backing of supervisory board
RE
03/22FDA Rejects Oral Treatment for Type 1 Diabetes - Update
DJ
03/22ALLERGAN : promises independent board chair in next leadership change
RE
03/22FDA Rejects Oral Treatment for Type 1 Diabetes
DJ
03/22UPS to Test In-Home Vaccine Service in U.S. -Reuters
DJ
More sector news : Pharmaceuticals - NEC
Chart SUMITOMO DAINIPPON PHARMA CO LTD
Duration : Period :
Sumitomo Dainippon Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 10
Average target price 2 365  JPY
Spread / Average Target -14%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda General Manager-Research Technology
Nobuyuki Hara Director, Executive Officer & GM-Development
Hitoshi Odagiri Director, Managing Executive Officer & GM-Sales
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO LTD-18.62%9 999
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409